Last update:
Immunology news
Immunology
Anxiety and insomnia may lower natural killer cell count, potentially repressing immune function
Natural killer (NK) cells are the bodyguards of our immune system. As a first line of defense, they destroy invading pathogens, foreign bodies, and infected cells in early stages, thereby preventing them from spreading. NK ...
7 hours ago
0
2
Immunology
Dietary restriction fuels T cells with ketones, boosting their cancer-fighting stamina
Reducing calorie intake helps cancer-fighting immune cells do their jobs more effectively, reports a study by Van Andel Institute scientists and collaborators. The findings lay the groundwork for developing dietary strategies ...
17 hours ago
0
14
Disarming cancer stem cells' shield makes immunotherapy more effective
Immunotherapy has revolutionized cancer care by training the immune system to detect and destroy tumors. For many patients, it works very well in shrinking tumors and sending cancer into remission, an undetectable state of ...
18 hours ago
0
0
Combination treatment shows large improvement in survival for people with relapsed myeloma
At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining teclistamab with daratumumab could help people with myeloma whose cancer has come back or hasn't responded ...
12 hours ago
0
1
Team discovers how to target 'undruggable' protein that fuels aggressive leukemia
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit a cancer-driving protein long considered impossible to target with drugs—a discovery that could open the ...
18 hours ago
0
0
Tec-Dara combination offers improvement over standard second-line therapies for relapsed, refractory multiple myeloma
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive ...
23 hours ago
0
0
Ianalumab+standard therapy extends time to treatment failure in patients with previously treated immune thrombocytopenia
Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or needing another treatment ...
23 hours ago
0
0
Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine ...
23 hours ago
0
0
Experimental antibody enables lasting platelet stability in autoimmune bleeding condition
More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening ...
Dec 9, 2025
0
0
Researchers find vital clue in the progression of Type 1 diabetes
Type 1 diabetes is a disease in which the body mistakenly attacks itself as the immune system destroys the pancreas's insulin-producing cells. Why the immune system turns against these cells remains one of the enduring questions ...
Dec 9, 2025
0
0
Next-gen CAR-T cell therapy shows early promise in patients with refractory B-cell acute lymphoblastic leukemia
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using the T-Charge platform, ...
Dec 9, 2025
0
0
Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression ...
Dec 9, 2025
0
0
Home-based monitoring could transform care for patients receiving T-cell redirecting therapies
Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects. Now new research by Fox Chase Cancer Center physicians shows that these patients can ...
Dec 9, 2025
0
0
New data highlight promise of pivekimab sunirine in two aggressive blood cancers
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive ...
Dec 9, 2025
0
0
Rethinking long-term allergy treatments: Experimental vaccine protects against anaphylaxis in mice
Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E antibodies in humanized mice, protects against Immunoglobulin E-mediated anaphylaxis, and shows no detectable ...
'Ready-made' T-cell gene therapy tackles 'incurable' T-cell leukemia
A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare ...
Dec 8, 2025
0
8
Immunotherapy works for sepsis thanks to precision approach
Immunotherapy for sepsis is effective when doctors tailor the treatment precisely to the patient's immune system condition. While earlier research showed little benefit of immunotherapy in sepsis, a new study demonstrates ...
Dec 8, 2025
0
19
A routine blood test could help predict who benefits most from CAR T-cell therapy
Measuring the lymphocytes—white blood cells that fight infection—in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians ...
Dec 8, 2025
0
0
CAR T cell therapy shows promising Phase II trial results in multiple myeloma
The chimeric antigen receptor (CAR) T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory multiple myeloma, according to new trial data from researchers at The ...
Dec 8, 2025
0
0
Continuous and fixed-duration treatments result in similar outcomes for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
Dec 8, 2025
0
1
New combination approach aims to make CAR T more durable in lymphoma
A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.
Dec 8, 2025
0
0
Milder chemotherapy proves effective for rare, aggressive lymphoma
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, ...
Dec 8, 2025
0
0
Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma
New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor (CAR) T cell therapy, ...
Dec 8, 2025
0
0
Prognostic tool could help clinicians identify high-risk cancer patients
Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate. Patients often relapse after receiving initial therapy, making it especially challenging for clinicians to ...
Dec 8, 2025
0
0
Hormonal fluctuations affect women's immunity, but a lack of rigor in studies still prevents a consensus
Hormonal fluctuations throughout a woman's life are among the factors that most influence the immune system. Like a seesaw, variations in estrogen and progesterone affect cellular levels and alter the immune and inflammatory ...
Dec 8, 2025
0
0
